Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i-GO feasibility study of ThermoDox plus MR-HIFU hyperthermia in metastatic breast cancer
NL-OMON55517Phase 1Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doxorubicin and cyclophosphamide in breast cancer, sponsored by University Medical Center Utrecht. Primary endpoints: Safety and tolerability and Feasibility of MR-HIFU plus ThermoDox treatment. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
doxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON55517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55517.